Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating
A wave of tau-targeted agents is progressing through the clinic, hoping to avoid the negative results from a first-in-class trial of a tau-targeted antibody.
After a decade of setbacks with anti-amyloid agents for Alzheimer disease, drug developers have turned their attention to tau, another hallmark of the deadly neurodegenerative disorder. More than ten tau-targeted candidates are currently in clinical trials, with several key efficacy readouts expected this year. The field could be in for a bumpy ride, if first results from Genentech and partner AC Immune’s anti-tau antibody semorinemab are anything to go by.